The Impact of the type of Menopause and Menopausal Duration on the Development of Pre-Diabetes Mellitus and Diabetes Mellitus in Postmenopausal Women

Banuhan ŞAHIN, Canan SOYER ÇALIŞKAN, Samettin ÇELİK, Hasan ULUBAŞ, Görker SEL

1Amasya University Sabuncuoglu Serefeddin Training and Research Hospital, Gynecology and Obstetrics Department, Amasya, Turkey
2Samsun Training and Research Hospital, Gynecology and Obstetrics Department, Samsun, Turkey
3Ministry of Health Ankara City Hospital, Gynecology and Obstetrics Department, Ankara, Turkey
4Zonguldak Bülent Ecevit University, Faculty of Medicine, Gynecology and Obstetrics Department, Zonguldak, Turkey

Cite this article as: Şahin B, Soyer Çalışkan C, Çelik S, Ulubaş H, Sel G. The Impact of the type of Menopause and Menopausal Duration on the Development of Pre-Diabetes Mellitus and Diabetes Mellitus in Postmenopausal Women. Türk Diyabet Obez 2020;3: 201-206.

ABSTRACT

Aim: The onset of menopause is an important factor determining quality of life in females. The aim of this study was to evaluate the effect of natural or surgical menopause, the duration of the menopausal period, and serum gonadotropin levels on the development of pre-diabetes mellitus (pre-DM) and diabetes mellitus (DM) in postmenopausal women.

Material and Methods: This retrospective study included 140 postmenopausal women with pre-DM, 148 postmenopausal women with DM and 265 healthy postmenopausal women. The groups were compared in respect of menopause type, the duration of the menopausal period, and serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels. Statistical evaluations were made.

Results: There was found to be no significant effect of natural or surgical menopause on the development of pre-DM or DM (p=0.393). Increased duration of menopause was mostly seen in women with DM and the difference was statistically significant compared to the controls (p=0.019). Serum decreased FSH and LH levels and increased E2 level were observed in the DM group and the difference was significant compared to the control group (respectively, p=0.001, p=0.001 and p=0.012).

Conclusion: The onset of natural or surgical menopause does not affect the development of pre-DM and DM. Women with DM have a longer menopausal period. Women with pre-DM and DM have lower serum FSH and LH levels and higher serum E2 levels. This can be explained in part by adiposity and insulin resistance.

Key Words: Diabetes mellitus, Natural menopause, Pre-diabetes mellitus, Surgical menopause

Menopoz Tipi ve Süresinin Postmenopozal Kadınlarda Pre-Diyabet ve Diyabet Gelişimine Etkisi

ÖZ

Amaç: Menopozal başlangıç kadınların hayat kalitesini belirleyen önemli faktörlerinden biridir. Bu çalışmanın amacı postmenopozal kadınlarda doğal veya cerrahi menopozlu olmanın, menopozal sürenin ve serum gonadotropinin düzeylerinin pre-diyabet (pre-DM) ve diyabet (DM) gelişimini özerine etkisini incelemektir.

Gereç ve Yöntemler: Bu retrospektif olgu kontrol çalışmasına 140 pre-DM, 148 pre-DM postmenopozal kadın ile 265 sağlıklı postmenopozal kadın dahil edildi. Grupların menopoz tipi, süresi ve serum folikül stimüle edici hormon (FSH), luteiniz edici hormon (LH) ve östradiol (E2) serum düzeyleri karşılaştırıldı. Istatistiksel değerlendirmede ANOVA ve Kruskal Wallis Testi kullanıldı.
INTRODUCTION

As a result of the loss of ovarian activity through natural or surgical means, menopause is the permanent termination of menstruation (1). This process, which is the end of the reproductive stage of life of a female, can give rise to many negative medical outcomes such as osteoporosis, cardiovascular disease, and diabetes mellitus (DM) (2). The menopausal transition is associated with significant changes in hormone profiles such as estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH) and these changes in hormones may play a role in the pathogenesis of the diseases in question (3).

Diabetes mellitus is the most commonly seen chronic disease in the period following menopause (4). As menopause is related to a reduction in pancreatic insulin secretion and elimination, very little change occurs in insulin levels in circulation. However, insulin resistance predisposes postmenopausal women to the development of DM, and this increases with age (5). Premature menopause and menopause created surgically with ovariectomy are associated with an increased risk of DM (6).

According to the results of the Study of the Prevalence of DM, Hypertension, Obesity and Endocrinological Diseases in Turkey (TURDEP-II), 45.3% (3.4 million people) of patients diagnosed with DM in Turkey are aged 40-59 years (7). DM is a multi-factor disease with both changeable (obesity, physical activity, unhealthy diet) and unchangeable (age, gender, family history of DM, polycystic ovary syndrome) risk factors (8). In 2002, the Turkish Menopause Association reported that the mean age of menopause in the country in general was 46.7 years (9).

The menopausal transition is characterized by increased testosterone and low sex hormone binding globulin (SHBG), which are related to DM (10). In a multicenter study, an increase in FSH during menopausal transition was found to be significantly related to a reduced risk of DM (11). It was shown in that study that when serum FSH increased (>50 IU/L) during the menopausal transition, the metabolic profile improved, and the risk of DM decreased (12). In postmenopausal women with high total and free serum testosterone and E2 levels, there seems to be a greater long-term risk of developing DM, independently of adiposity and insulin resistance (13).

The aim of this study was to investigate the effect of natural or surgical menopause, the duration of the menopausal period, and serum gonadotropin levels on the development of pre-DM and DM in postmenopausal women.

MATERIAL and METHODS

This retrospective cross-sectional study included postmenopausal women who underwent routine annual examination in the polyclinics of the Samsun Women and Children’s Health Training and Research Hospital between 1 January 2016 and 1 June 2019. Approval for the study was granted by the Local Ethics Committee of Samsun Training and Research Hospital (decision no: GOKA / 2019/3/10).

The subjects included in the study were naturally or surgically postmenopausal women, aged 40-65 years, who were not using hormone replacement therapy (HRT). Exclusion criteria were chemotherapy applied for cancer, the use of exogenous steroid treatment or anti-lipid medication, or a history of pelvic radiotherapy.

From a total of 602 postmenopausal women identified, exclusion criteria were applied to 21 with HRT use, as the potential effects of estrogen and progesterone are masked in the relationship between menopause and lipid metabolism, and to 28 who were receiving chemotherapy. Thus, evaluation was made of 140 women diagnosed with pre-DM after menopause, 148 women diagnosed with DM after menopause and 265 healthy postmenopausal women. Comparisons were made of these three groups in respect of menopause type (natural/surgical), time since menopause, and gonadotropin (FSH, LH, E2) levels.

Menopause was accepted as a menorrhea for at least 12 consecutive months and FSH level >40 IU/L (14). Demographic characteristics were recorded of age, gravida, parity, the time since onset of menopause and body mass index (BMI). Height and weight were measured, and BMI was calculat-
ed as weight (kg)/height (m²). Waist circumference was measured with a flexible band placed around the body in the horizontal plane at the level of the iliac crest while standing.

Venous blood samples were taken in the morning after a 12-hour fasting. Glucose, HbA1c, FSH, LH, and E2 values were examined using a 7600-110 Automatic Analyser (Hitachi Inc., Tokyo, Japan).

In accordance with the American Diabetes Association (ADA) criteria, the diagnosis of DM was made with fasting plasma glucose level of ≥126 mg/dL or ≥6.5% HbA1c value or the use of insulin, and the diagnosis of pre-DM with glucose level of 100-125 mg/dL or HbA1c of 5.7-6.4 (15).

Statistical Analysis

Data obtained in the study were analyzed statistically using NCSS software (Number Cruncher Statistical System, 2007, Kaysville, Utah, USA). Descriptive statistical methods were used when evaluating the data (mean, standard deviation and median (minimum-maximum) (when assumptions are not provided) for numerical data; number (n) and percentage (%) for categorical data). Conformity of quantitative data to normal distribution was assessed with the Kolmogorov-Smirnov test and graphic evaluations. In the comparison of 3 or more groups of data showing normal distribution, the One-Way Anova test was used, and the Tukey test was used in the comparisons of paired groups. In the comparisons of data not showing normal distribution, the Kruskal-Wallis test was applied to 3 groups or more, and the Dunn-Bonferroni was used in the comparisons of paired groups. The Pearson Chi-square test was applied to the comparisons of qualitative data. A value of p<0.05 was accepted as statistically significant.

RESULTS

A total of 553 postmenopausal women were evaluated in this study. No significant difference was determined in respect of age, gravida, parity and number of abortus when pre-DM and DM groups were compared with the control group. BMI and waist circumference values were found to be increased in the pre-diabetic and diabetic groups (Table 1).

There was found to be no significant effect of natural or surgical menopause on the development of pre-DM or DM (p=0.393). Increased mean duration of menopause was mostly seen in women with DM and the difference was sta-

| Table 1: Descriptive and clinical characteristics of the postmenopausal women according to glycemic status. |
|-----------------------------------------------------------------------------------|
| Control (n=265) | Pre-DM (n=140) | DM (n=148) | p value |
|---|---|---|---|
| Age (year) | 55.52 ± 8.86 | 56.36 ± 9.28 | 57.66 ± 8.74 | 0.068A |
| Gravida | 3 (0-15) | 4 (0-15) | 4 (0-16) | 0.088B |
| Parity | 3 (0-7) | 3 (0-8) | 3 (0-10) | 0.122B |
| Abortus | 1 (0-5) | 1 (0-4) | 1 (0-6) | 0.199B |
| BMI (kg/m²) | 29.35 ± 5.00a | 31.02 ± 6.04ab | 33.94 ± 6.29bc | 0.001A |
| Waist circumference (cm) | 85.20 ± 11.80ab | 85.39 ± 9.35ab | 90.42 ± 12.29c | 0.001A |
| Type of menopause | | | | |
| Natural | 188 (70.9%) | 107 (76.4%) | 112 (75.7%) | 0.393C |
| Surgical | 77 (29.1%) | 33 (23.6%) | 36 (24.3%) | |
| Duration of menopause (year) | 6.86 ± 6.22a | 7.77 ± 6.73ab | 8.71 ± 7.28bc | 0.019A |

BMI: Body mass index. A: One-way ANOVA Test, mean ± standard deviation; B: Kruskal Wallis Test, median (minimum-maximum); C: Pearson Chi-square Test, n (%). a-b-c: There is no difference between groups labeled under the same letter.

| Table 2: Laboratory test results of the postmenopausal women according to glycemic status. |
|-----------------------------------------------------------------------------------|
| Control (n=265) | Pre-DM (n=140) | DM (n=148) | p value |
|---|---|---|---|
| Glucose (mg/dL) | 85.66 ± 16.57 | 112.22 ± 14.58 | 130.52 ± 19.88 | 0.035A |
| HbA1c (%) | 5.2 (5.0-5.6)a | 6.1 (5.5-6.4)bc | 6.7 (5.0-11.9)bc | 0.048B |
| FSH (IU/L) | 71.83 ± 28.22a | 62.97 ± 25.76bc | 55.80 ±22.16bc | 0.001A |
| LH (IU/L) | 46.57 ± 24.25a | 40.95 ± 36.62bc | 37.64 ± 22.69bc | 0.001A |
| E2 (ng/L) | 31.38 ± 33.29a | 33.74 ± 26.17abc | 37.10 ± 29.36bc | 0.012A |

FSH: follicle stimulating hormone, LH: luteinizing hormone, E2: estradiol. A: One-way ANOVA Test, mean ± standard deviation; B: Kruskal Wallis Test, median (minimum-maximum). a-b-c: There is no difference between groups labeled under the same letter.
hormone treatment because of surgical menopause may be
production and secretion (24). However, taking exogenous
tein metabolism caused by a reduction in ovarian steroid
both glucose and insulin metabolism and lipid and lipopro-
elss increase, and SHBG levels decrease. Testosterone and
while E2 terminates ovarian production, testosterone lev-
menopause was not observed to have an effect on the devel-
ment of pre-DM or DM. However, increased duration of
opause was detected women with DM and then women
with pre-DM. In addition, at least serum FSH and LH levels
E2 levels were detected in women with DM.
Menopause is associated with changes in body composition
such as increased abdominal fat and reduced body muscle
mass (16). The emergence of hyperglycemia in this period
may be a direct result of ovarian failure or indirectly a result
of central fat redistribution related to E2 deficiency (17). A
previous study reported that no significant difference was
seen between premenopausal and postmenopausal women
in respect of the presence of type 2 DM, impaired glucose
tolerance, impaired fasting glucose and other cardiometab-
olic signs (18).
The risk of DM is known to increase with advancing age. An
increase in the duration of the postmenopausal period also
increases the risk of DM development (19). In the current
study, the mean duration of the postmenopausal period
was found to be significantly longer in the pre-DM and DM
groups than in the control group.
Natural menopause is characterized by increasing relative
androgenicity, which has been reported to be related to
glucose metabolism (20). In the postmenopausal period,
while E2 terminates ovarian production, testosterone lev-
levels increase, and SHBG levels decrease. Testosterone and
SHBG levels have been associated with insulin resistance
and DM (21). Unlike natural menopause when falls in E2
occur within a few years, in surgical menopause created by
bilateral oophorectomy, E2 ovarian production is cut rap-
idly and the reproductive life is suddenly terminated. Two
previous studies have shown that there is a greater risk of
DM in women with surgical menopause (22, 23).
Having undergone oophorectomy leads to impairment in
both glucose and insulin metabolism and lipid and lipopro-
tein metabolism caused by a reduction in ovarian steroid
production and secretion (24). However, taking exogenous
hormone treatment because of surgical menopause may be
a treatment option with a protective effect against the risk of
DM, which is already increased in females (25). In the cur-
rent study, no difference was determined between women
with natural or surgical menopause in respect of postmeno-
pausal development of pre-DM and DM. This result could
be attributed to the fact that almost three-quarters of the
women in all 3 groups had undergone natural menopause.

After menopause, E2 production shifts from the ovaries to
fat tissue. The formation of relatively more fat tissue may
play a large role in increasing the risk of DM with an insuffi-
cient decrease in endogenous E2 levels and even by forming
insulin resistance related to obesity (26). Premenopausal
FSH levels have been reported not to show any difference
between obese and non-obese females, but a significantly
lower increase in FSH and therefore lower FSH levels have
been reported in postmenopausal obese women (27).

In a study of postmenopausal women not using HRT, it
seems to be a significant inverse correlation of serum FSH
value with fasting glucose and HbA1c (28). In the current
study, the lowest serum FSH and LH levels were seen in
women with DM. In other words, the FSH and LH values of
the newly diagnosed pre-DM and DM women were lower
than those of the control group. In addition, the serum E2
values of these women were determined to be higher. The
BMI and waist circumference measurements of the post-
menopausal women in the pre-DM and DM groups were
also found to be higher than those of the control group.
The results of this study showed that when postmenopausal
women gain weight and increase abdominal fat, the endog-
enous E2 levels do not fall sufficiently and the serum FSH
and LH values do not increase sufficiently, thereby leading
to an increased possibility of the development of pre-DM
and DM. However, it is difficult to directly compare the cur-
rent study findings of low FSH, low LH, and high E2 val-
ues in postmenopausal women with pre-DM and DM with
studies of DM in the postmenopausal period, and to make
generalizations because the premenopausal levels of FSH,
LH and E2 of the current study participants were not ex-
amined. There is a need for further longitudinal studies on
this subject.

Limitations of this study can be said to be the retrospective
design and the limited number of postmenopausal women.
No OGTT was applied for the diagnosis of dysglycemia and
this could have caused an underestimation of the relation-
ships between menopause and DM prevalence. There is a
need for further prospective studies including OGTT data
to confirm the results of this study.

In conclusion, the onset of menopause naturally or surgical-
ly was not determined to have had an effect on the develop-
The Development of Pre-Diabetes Mellitus and Diabetes Mellitus in Postmenopausal Women

ment of pre-DM or DM, but with an increase in the menopausal period there was seen to be an increase in pre-DM and DM. As the majority of women with DM are in the older population, and the majority of DM cases are diagnosed in the postmenopausal period, the common effect on other comorbidities of this status makes it a critical public health priority. When it is considered that obesity plays an important role in FSH, LH and E2 levels in the risk of developing DM, providing weight control at an earlier age is important for the prevention of DM which could develop later.

Ethical Approval
Approval for the study was granted by the Local Ethics Committee of Samsun Training and Research Hospital (decision no: GOKA / 2019/3/10).

Conflict of Interests
The authors have no conflict of interests to declare.

Financial Disclosure
There is no financial support for the study.

Author Contributions
Study concept / Design: Canan Soyer, Samettin Çelik, Data collecting: Canan Soyer, Samettin Çelik, Hasan Ulubasoğlu, Data analysis and interpretation: Banuhan Şahin, Post draft: Banuhan Şahin, Görker Sel, Critical review of the content: Banuhan Şahin, Final approval and responsibility: Banuhan Şahin, Göker Sel.

Peer Review Process
Extremely reviewed and accepted.

Acknowledgements
The authors thank all the project participants for their contributions.

REFERENCES
1. Mishra G, Kuh D. Perceived change in quality of life during the menopause. Soc Sci Med. 2006;62:93-102.
2. Cheung E, Tsang S, Bow C, Soong C, Yeung S, Loong C, et al. Bone loss during menopausal transition among southern Chinese women. Maturitas. 2011;69:50-56.
3. Minkin MJ. Menopause: Hormones, Lifestyle, and Optimizing Aging. Obstet Gynecol Clin North Am. 2019;46:501-514.
4. Stachowiak G, Pertyński T, Pertyńska-Marczewska M. Metabolic disorders in menopause. Prz Menopauzalny. 2015;14:59-64.
5. Korytkowski MT, Krug EL, Daly MA, Deriso L, Wilson JW, Winters SJ. Does androgen excess to the cardiovascular risk profile in postmenopausal women with type 2 diabetes? Metabolism. 2005;54:1626-1631.
6. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and Type 2 diabetes prevention: Evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38:173-188.
7. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dincçag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and pre-diabetes in Turkish adults. Eur J Epidemiol. 2013;28:169-180.
8. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus present and future perspectives. Nat Rev Endocrinol. 2012;8:228-236.
9. Çiçek M, Akyürek C, Çelik Ç, Haberal A. Kadın hastalıkları ve doğum bilgisi. Güneş Kitabevi, Ankara, 2004;1163-1180.
10. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2006;295:1288-1299.
11. Park SK, Harlow SD, Zheng H, Karonen-Gutierrez C, Thurston RC, Ruppert K, et al. Association between changes in oestriodial and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet Med. 2017;34:531-538.
12. Cheung CL, Kung AWC, Tan KCB. Serum follicle stimulating hormone is associated with reduced risk of diabetes in postmenopausal women: The Hong Kong osteoporosis study. Maturitas. 2018;114:41-45.
13. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94:4127-4135.
14. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril. 2012;97:843-851.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):62-69.
16. Stefanska A, Cembrowska P, Kubacka J, Kuligowska-Prusinska M, Sypniewska G. Gonadotropins and their association with the risk of prediabetes and type 2 diabetes in middle-aged postmenopausal women. Dis Markers. 2019;5:2384069.
17. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-2411.
18. Soriguer F, Morcillo S, Hernando V, Valdés S, Ruiz de Adana MS, Oliveira G, et al. Type 2 diabetes mellitus and other cardiovascular risk factors are no more common during menopause: Longitudinal study. Menopause. 2009;16:817-821.
19. Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol. 2009;5:553-558.
20. Kim C. Does menopause increase diabetes risk? Strategies for diabetes prevention in midlife women. Womens Health (LondEngl). 2012;8:155-167.
21. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K, et al. Menopause and the metabolic syndrome: The study of women’s health across the nation. Arch Intern Med. 2008;168:1568-1575.
22. Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37:725-733.

23. Lejskova M, Pi’ha J, Adamkova S, Auzký O, Adámek T, Babková E, et al. Bilateral oophorectomy may have an unfavorable effect on glucose metabolism compared with natural menopause. Physiol Res. 2014;63(Suppl 3):395-402.

24. Carr MC, Kim KH, Zambon A, Mitchell ES, Woods NF, Casazza CP, et al. Changes in LDL density across the menopausal transition. J Investig Med. 2000;48:245-250.

25. Godsland IF. Oestrogens and insulin secretion. Diabetologia 2005;48:2213-2220.

26. Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: Effect of age at the final menstrual period. J Clin Endocrinol Metab 2011;96:746-754.

27. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab. 2007;92:3060-3067.

28. Wang N, Kuang L, Han B, Li Q, Chen Y, Zhu C, et al. Follicle-stimulating hormone associates with prediabetes and diabetes in postmenopausal women. Acta Diabetol. 2016;53:227-236.